*ALK* rearrangement detection using fluorescence *in situ* hybridisation (FISH) or dichotomous immunohistochemical staining (IHC) is a standard test to identify patients with NSCLC eligible for treatment with ALK inhibitors .
A European, prospective, multicentre study compared response to treatment with crizotinib in ALK FISH+ and ALK FISH- in patients with ALK IHC+. Central collection of stage 4 ALK IHC+ NSCLC cases treated with crizotinib took place from April 2014 to November 2017. Slides were centrally validated for ALK IHC and ALK FISH. Monthly recording showed that of 3,523 registered ALK IHC tests, 94 (2.6%) were ALK IHC+; less than 0.01% were ALK IHC+ FISH- cases. Local ALK FISH analysis identified 46 concordant (ALK IHC+/FISH+) cases and 18 that were discordant (ALK IHC+/FISH-).
Central validation in Antwerp, Belgium, found 37 concordant and 6 discordant cases, 5 of which had follow-up. Limited tissue in the biopsy samples hampered validation. Time to tr...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Accumulation of concomitant mutations involved in drug resistance in sequential ALK TKI treatments of *ALK*-positive NSCLC Next Article
Unmet needs in surgical management of malignant pleural mesothelioma »
Table of Contents: WCLC 2018
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.